Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
According to the report, Telix has achieved a revenue of US$206M.
Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, "We believe this is a solid result, particularly in light of the reimbursement dynamics during the quarter. Moreover, a 3% increase in dose volumes suggests competitive pricing pressures are beginning to stabilize.
Telix has entered Q4 in a position of strength, supported by a growing customer base, two FDA-approved PSMA imaging agents, and CMS reimbursement for Gozellix effective from 1 October in the U.S.
The company's two-product strategy enables it to expand market share across all customer segments, with Gozellix enhancing production flexibility and providing customer choice based on patient reimbursement pathways.
Author's summary: Telix reports $206M revenue with upgraded FY 2025 guidance.